AZILECT

Compare AZILECT  to:
Compare
Compare

Generic Name for AZILECT

Rasagiline 0.5mg, 1mg; tabs.

Legal Classification:

Rx

Pharmacological Class for AZILECT

MAO-B inhibitor.

Manufacturer of AZILECT

Teva Neuroscience

Indications for AZILECT

Idiopathic Parkinson's disease, as initial monotherapy and as an adjunct to levodopa.

Adult dose for AZILECT

Monotherapy: 1mg once daily. Adjunctive therapy: initially 0.5mg once daily; may increase to 1mg once daily (consider reducing levodopa dose if side effects increase). Mild hepatic impairment (Child-Pugh score 5–6) or concomitant CYP1A2 inhibitors: 0.5mg once daily.

Children's dosing for AZILECT

Not recommended.

Contraindications for AZILECT

During or within 2 weeks of meperidine, tramadol, propoxyphene, methadone, MAOIs. Concomitant dextromethorphan, St. John's wort, cyclobenzaprine.

Warnings/Precautions for AZILECT

Avoid tyramine-rich foods (see literature). Mild hepatic impairment: reduce dose; moderate to severe hepatic impairment (Child-Pugh score ≥7): not recommended. Monitor for melanoma. Pregnancy (Cat.C). Nursing mothers.

Interactions for AZILECT

See Contraindications. Possible hypertensive crisis with excess dietary tyramine (see literature). Potentiated by CYP1A2 inhibitors (eg, ciprofloxacin). Severe CNS toxicity (hyperpyrexia, death) with triazolopyridines, tricyclics, tetracyclics, SSRIs, SNRIs, and MAOIs (both nonselective and type B selective); allow at least 14 days after discontinuing rasagiline before starting triazolpyridines, tricyclics, tetracyclics, SSRIs, or SNRIs; allow 5 weeks after discontinuing fluoxetine before starting rasagiline. Caution with sympathomimetics (eg, nasal, oral, ophthalmic decongestants or cold remedies).

Adverse Reactions for AZILECT

As monotherapy: flu syndrome, arthralgia, depression, dyspepsia. With levodopa: also dyskinesia, accidental injury, weight loss, postural hypotension, GI upset, anorexia, abdominal pain, constipation, dry mouth, rash, abnormal dreams, fall.

How is AZILECT supplied?

Tabs—30

Related Disease:

Parkinsonism

Related Resources

FDA reviews cardiovascular risks associated with Stalevo

August 23, 2010

The FDA has notified healthcare professionals that clinical trial data suggesting that Stalevo (carbidopa, levodopa, entacapone, from Novartis) increases the risk for cardiovascular events compared to carbidopa/levodopa (Sinemet, from Bristol-Myers Squibb) is being evaluated.

FDA launches "Bad Ad Program" to detect misleading drug ads

May 11, 2010

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.

Phase 2 study of Serdaxin for the treatment of Parkinson's disease (PD)

April 06, 2010

Rexahn announced that it has submitted a Phase 2 protocol to the FDA for the study of Serdaxin for the treatment of Parkinson's disease (PD).

FDA evaluating prostate cancer risk with Stalevo

March 31, 2010

The FDA has notified healthcare professionals and patients that it is evaluating data from the long-term STRIDE-PD clinical trial, that may suggest that patients taking Stalevo (carbidopa/levodopa/entacapone, from Novartis) may be at an increased risk for developing prostate cancer.

Mirapex ER approved for advanced Parkinson's Disease

March 23, 2010

The FDA has approved Mirapex ER (pramipexole dihydrochloride extended-release tablets, from Boehringer Ingelheim) for the signs and symptoms of advanced idiopathic Parkinson's disease (PD).

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions